Friedberg EC. A brief history of the DNA repair field. Cell Res. 2008;18:3–7.
Article
CAS
PubMed
Google Scholar
Gourley C, Balmana J, Ledermann JA, et al. Moving from poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol. 2019;37:2257–69.
Article
CAS
PubMed
Google Scholar
Reinhardt HC, Jiang H, Hemann MT, et al. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle. 2009;8:3112–9.
Article
CAS
PubMed
Google Scholar
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.
Article
CAS
PubMed
Google Scholar
Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lin KY, Kraus WL. PARP inhibitors for cancer. Therapy Cell. 2017;169:183.
CAS
PubMed
Google Scholar
Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10:293–301.
Article
CAS
PubMed
PubMed Central
Google Scholar
Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol. 2011;22:268–79.
Article
CAS
PubMed
Google Scholar
Qi H, Price BD, Day TA. Multiple roles for mono- and poly(ADP-Ribose) in regulating stress responses. Trends Genet. 2019;35:159–72.
Article
CAS
PubMed
Google Scholar
Vyas S, Matic I, Uchima L, et al. Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat Commun. 2014;5:4426.
Article
CAS
PubMed
Google Scholar
Schleicher EM, Galvan AM, Imamura-Kawasawa Y, et al. PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress. Nucleic Acids Res. 2018;46:8908–16.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cho TE, Bott D, Ahmed S, et al. 3-Methylcholanthrene induces chylous ascites in TCDD-inducible poly-ADP-Ribose Polymerase (Tiparp) knockout mice. Int J Mol Sci. 2019;20:2312.
Article
CAS
PubMed Central
Google Scholar
Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell. 2011;145:30–8.
Article
CAS
PubMed
Google Scholar
Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.
Article
CAS
PubMed
Google Scholar
Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.
Article
CAS
PubMed
Google Scholar
Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16:110–20.
Article
CAS
PubMed
Google Scholar
Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–99.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yi M, Dong B, Qin S, et al. Advances and perspectives of PARP inhibitors. Exp Hematol Oncol. 2019;8:29.
Article
PubMed
PubMed Central
CAS
Google Scholar
Jiang X, Li W, Li X, et al. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag Res. 2019;11:4371–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17:1579–89.
Article
CAS
PubMed
Google Scholar
Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018;19:1126–34.
Article
PubMed
PubMed Central
Google Scholar
Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.
Article
CAS
PubMed
Google Scholar
Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–27.
Article
PubMed
PubMed Central
Google Scholar
Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pearre DC, Tewari KS. Targeted treatment of advanced ovarian cancer: spotlight on rucaparib. Ther Clin Risk Manag. 2018;14:2189–201.
Article
CAS
PubMed
PubMed Central
Google Scholar
Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.
Article
CAS
PubMed
Google Scholar
Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111–5.
Article
CAS
PubMed
Google Scholar
Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Swisher EM, Sakai W, Karlan BY, et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Can Res. 2008;68:2581–6.
Article
CAS
Google Scholar
Kondrashova O, Nguyen M, Shield-Artin K, et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7:984–98.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9:3970.
Article
PubMed
PubMed Central
CAS
Google Scholar
Veeck J, Ropero S, Setien F, et al. BRCA1 CpG Island Hypermethylation predicts sensitivity to Poly(Adenosine Diphosphate)-ribose polymerase inhibitors. J Clin Oncol. 2010;28:e563–e564564.
Article
PubMed
Google Scholar
Esteller M. Epigenetics in Cancer. N Engl J Med. 2008;358:1148–59.
Article
CAS
PubMed
Google Scholar
Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564–9.
Article
CAS
PubMed
Google Scholar
D'Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst). 2018;71:172–6.
Article
CAS
Google Scholar
Lord CJ, Tutt ANJ, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 2015;66:455–70.
Article
CAS
PubMed
Google Scholar
Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-Ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015;33:1397–406.
Article
CAS
PubMed
PubMed Central
Google Scholar
Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5:1137–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Feng FY, de Bono JS, Rubin MA, et al. Chromatin to clinic: the molecular rationale for PARP1 inhibitor function. Mol Cell. 2015;58:925–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pommier Y, O’Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8:362ps17.
Article
PubMed
CAS
Google Scholar
Yang L, Zhang Y, Shan W, et al. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med. 2017;9:eaal1645.
Article
PubMed
PubMed Central
CAS
Google Scholar
Karakashev S, Zhu H, Yokoyama Y, et al. BET bromodomain inhibition synergizes with parp inhibitor in epithelial ovarian cancer. Cell Rep. 2017;21:3398–405.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sun C, Yin J, Fang Y, et al. BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency. Cancer Cell. 2018;33:401–16.
Article
CAS
PubMed
PubMed Central
Google Scholar
Davies OR, Forment JV, Sun M, et al. CtIP tetramer assembly is required for DNA-end resection and repair. Nat Struct Mol Biol. 2015;22:150.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yun MH, Hiom K. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature. 2009;459:460.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bunting SF, Callen E, Wong N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141:243–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jaspers JE, Kersbergen A, Boon U, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013;3:68–81.
Article
CAS
PubMed
Google Scholar
Xu G, Chapman JR, Brandsma I, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015;521:541.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gupta R, Somyajit K, Narita T, et al. DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity. Cell. 2018;173:972–988.e23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Noordermeer SM, Adam S, Setiaputra D, et al. The shieldin complex mediates 53BP1-dependent DNA repair. Nature. 2018;560:117–21.
Article
CAS
PubMed
PubMed Central
Google Scholar
Johnson N, Johnson SF, Yao W, et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci. 2013;110:17041–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ray Chaudhuri A, Callen E, Ding X, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535:382.
Article
PubMed
CAS
Google Scholar
Znojek P, Willmore E, Curtin NJ. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br J Cancer. 2014;111:1319.
Article
CAS
PubMed
PubMed Central
Google Scholar
Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs. 2012;30:1493–500.
Article
CAS
PubMed
Google Scholar
Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response. Mol Cell. 2017;66:801–17.
Article
CAS
PubMed
Google Scholar
Kastan MB, Lim D-S. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000;1:179–86.
Article
CAS
PubMed
Google Scholar
Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160–6.
Article
CAS
PubMed
Google Scholar
Coyne GHOS, Do KT, Kummar S, et al. Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors. J Clin Oncol. 2018;36:2549–2549.
Article
Google Scholar
Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 Inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 2016;17:2367–81.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bajrami I, Frankum JR, Konde A, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Can Res. 2014;74:287–97.
Article
CAS
Google Scholar
Blazek D, Kohoutek J, Bartholomeeusen K, et al. The cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 2011;25:2158–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Joshi PM, Sutor SL, Huntoon CJ, et al. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem. 2014;289:9247–53.
Article
CAS
PubMed
PubMed Central
Google Scholar
Garcia TB, Snedeker JC, Baturin D, et al. A small-molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Mol Cancer Ther. 2017;16:2058–68.
Article
CAS
PubMed
PubMed Central
Google Scholar
Geenen JJJ, Schellens JHM. Molecular pathways: targeting the protein kinase Wee1 in cancer. Clin Cancer Res. 2017;23:4540–4.
Article
CAS
PubMed
Google Scholar
Guertin AD, Li J, Liu Y, et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther. 2013;12:1442–52.
Article
CAS
PubMed
Google Scholar
Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci. 2016;37:872–81.
Article
CAS
PubMed
Google Scholar
Porter CC, Kim J, Fosmire S, et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia. 2012;26:1266.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ford JB, Baturin D, Burleson TM, et al. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget. 2015;6:28001.
Article
PubMed
PubMed Central
Google Scholar
Harris PS, Venkataraman S, Alimova I, et al. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer. 2014;13:72.
Article
PubMed
PubMed Central
CAS
Google Scholar
Rajeshkumar NV, De Oliveira E, Ottenhof N, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011;17:2799–806.
Article
CAS
PubMed
PubMed Central
Google Scholar
Krajewska M, Heijink AM, Bisselink YJWM, et al. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene. 2013;32:3001–8.
Article
CAS
PubMed
Google Scholar
Bryant HE, Petermann E, Schultz N, et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009;28:2601–15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Domínguez-Kelly R, Martín Y, Koundrioukoff S, et al. Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol. 2011;194:567–79.
Article
PubMed
PubMed Central
CAS
Google Scholar
Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci. 2008;105:17079–844.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kievit FM, Wang FY, Fang C, et al. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J Control Release. 2011;152:76–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Batrakova EV, Kabanov AV. Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release. 2008;130:98–106.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen Y, Zhang W, Gu J, et al. Enhanced antitumor efficacy by methotrexate conjugated Pluronic mixed micelles against KBv multidrug resistant cancer. Int J Pharm. 2013;452:421–33.
Article
CAS
PubMed
Google Scholar
Patel NR, Rathi A, Mongayt D, et al. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm. 2011;416:296–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Meng H, Mai WX, Zhang H, et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano. 2013;7:994–1005.
Article
CAS
PubMed
PubMed Central
Google Scholar
Amiri-Kordestani L, Basseville A, Kurdziel K, et al. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updates. 2012;15:50–61.
Article
CAS
Google Scholar
Du Y, Yamaguchi H, Wei Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016;22:194.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351–79.
Article
CAS
PubMed
Google Scholar
Moskwa P, Buffa FM, Pan Y, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to parp inhibitors. Mol Cell. 2011;41:210–20.
Article
CAS
PubMed
Google Scholar
Choi Young E, Meghani K, Brault M-E, et al. Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant ovarian cancer. Cell Rep. 2016;14:429–39.
Article
PubMed
PubMed Central
CAS
Google Scholar
Morales J, Li L, Fattah FJ, et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 2014;24:15–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798–811.
Article
CAS
PubMed
PubMed Central
Google Scholar
Murai J, Huang S-YN, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–99.
Article
CAS
PubMed
PubMed Central
Google Scholar
Velcheti V, Schalper K. Basic overview of current immunotherapy approaches in cancer. Am Soc Clin Oncol Educ Book. 2016;36:298–308.
Article
Google Scholar
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23:3711–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li A, Yi M, Qin S, et al. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol. 2019;12:98.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lee EK, Konstantinopoulos PA. Combined PARP and immune checkpoint inhibition in ovarian cancer. Trends Cancer. 2019;5:524–8.
Article
CAS
PubMed
Google Scholar
Higuchi T, Flies DB, Marjon NA, et al. CTLA-4 blockade synergizes therapeutically with PARP Inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015;3:1257–68.
Article
CAS
PubMed
PubMed Central
Google Scholar
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the Pd-1 Immunoinhibitory receptor by a Novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
Article
CAS
PubMed
Google Scholar
Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95–106.
Article
CAS
PubMed
Google Scholar
Robert L, Tsoi J, Wang X, et al. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire. Clin Cancer Res. 2014;20:2424–32.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gupta SK, Kizilbash SH, Carlson BL, et al. Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma. J Natl Cancer Inst. 2016;108.
Article
PubMed
PubMed Central
CAS
Google Scholar
Smith MA, Reynolds CP, Kang MH, et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015;21:819–32.
Article
CAS
PubMed
Google Scholar
Tentori L, Leonetti C, Scarsella M, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002;99:2241–4.
Article
CAS
PubMed
Google Scholar
Cheng CL, Johnson SP, Keir ST, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther. 2005;4:1364–8.
Article
CAS
PubMed
Google Scholar
Sarkaria JN, Kitange GJ, James CD, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573–84.
Article
CAS
PubMed
Google Scholar
Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16:87–97.
Article
CAS
PubMed
Google Scholar
Loibl S, O'Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:497–509.
Article
CAS
PubMed
Google Scholar
Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8:374.
Article
PubMed
PubMed Central
CAS
Google Scholar
Li L, Karanika S, Yang G, et al. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10:eaam7479.
Article
PubMed
PubMed Central
CAS
Google Scholar
Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19:975–86.
Article
CAS
PubMed
Google Scholar
Sun C, Fang Y, Yin J, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017;9:eaal5148.
Article
PubMed
PubMed Central
Google Scholar
Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yates LR, Knappskog S, Wedge D, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017;32:169–184.e7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sizemore ST, Mohammad R, Sizemore GM, et al. Synthetic lethality of PARP inhibition and ionizing radiation is p53-dependent. Mol Cancer Res. 2018;16:1092–102.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jiang J, Yang ES, Jiang G, et al. p53-Dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Can Res. 2011;71:5546–57.
Article
CAS
Google Scholar
Yang ES, Nowsheen S, Rahman MA, et al. Targeting BRCA1 localization to augment breast tumor sensitivity to Poly(ADP-Ribose) polymerase inhibition. Can Res. 2012;72:5547–55.
Article
CAS
Google Scholar
Feng Z, Kachnic L, Zhang J, et al. DNA damage induces p53-dependent BRCA1 nuclear export. J Biol Chem. 2004;279:28574–84.
Article
CAS
PubMed
Google Scholar